Why the study?
Does honokiol reduce ventricular arrhythmias and infarct size in a rat model of coronary ligation?
Does honokiol reduce ventricular arrhythmias and infarct size in a rat model of coronary ligation?
Honokiol demonstrates myocardial protective effects by reducing infarct size and suppressing ventricular arrhythmias during ischemia and reperfusion in a rat model.
Hypothesis-generating for honokiol in myocardial ischemia; human trials needed before any clinical consideration.
Honokiol is an active component of Magnolia officinalis. It was reported to be 1000 times more potent than alpha-tocopherol in inhibiting lipid peroxidation in rat heart mitochondria. In this study, we investigated the in vivo antiarrhythmic and antiischemic effects of honokiol in coronary ligated rats. Male Sprague-Dawley rats were anesthetized with urethane. Honokiol, at dosages of 10(-7) g/kg, 10(-8) g/kg, and 10(-9) g/kg, was administered intravenously 15 min before ligation of the coronary artery. Incidence and duration of ventricular tachycardia and ventricular fibrillation during 30 min coronary ligation were significantly reduced by 10(-7) g/kg honokiol. Ventricular arrhythmia during 10 min reperfusion after the relief of coronary ligation was also reduced. In rats subjected to 4 hours coronary ligation, 10(-7) g/kg, 10(-8) g/kg, and 10(-9) g/kg honokiol significantly reduced the infarct zone. We concluded that honokiol may protect the myocardium against ischemic injury and suppress ventricular arrhythmia during ischemia and reperfusion.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: